Callitas Health Inc.

Callitas Health expects to roll out 'ToConcieve' product in the fourth quarter

Callitas Health (CSE:LILY, OTCQB:MPHMF, OTCMKTS: MPHMF) CEO James Thompson tells Proactive Investors that the clinical-stage pharmaceutical company is working through the R&D phase to get its ToConceive product onto retail shelves by the fourth quarter.

In March, Callitas announced a partnership with NFI Consumer Healthcare, the maker of pregnancy test kit e.p.t. to package the company's fertility lubricant. Callitas expects to see revenue from NFI in the second half of this year.

Quick facts: Callitas Health Inc.

Price: $0.11

Market: CSE
Market Cap: $3.62 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Callitas Health Inc. named herein, including the promotion by the Company of Callitas Health Inc. in any Content on the Site, the Company...



Callitas Therapeutics signs LOI with Simply Wholeistic, updates on THC & CBD...

Callitas Therapeutics (CSE:LILY) (OTCQB:MPHMF) Vice President of Sales & Business Development Joshua Maurice tells Proactive Investors the pharma company has signed a letter of intent with Simply Wholeistic to manufacture  its CannaStrip products in the U.S. Maurice added that as...

on 04/25/2019

2 min read